Status: Currently Official on 15-Feb-2025
Official Date: Official as of 01-Nov-2023
Document Type: USP Monographs
DocId: GUID-4FC1F38F-064C-4F73-8E5C-E02F805E7143_8_en-US
DOI: https://doi.org/10.31003/USPNF_M10968_08_01
DOI Ref: o8sts

Morphine Sulfate Compounded Injection

DEFINITION

Morphine Sulfate Compounded Injection contains NLT 90.0% and NMT 110.0% of the labeled amount of morphine sulfate pentahydrate $[(C_{17}H_{19}NO_3)_2 \cdot H_2SO_4 \cdot 5H_2O]$.

Prepare Morphine Sulfate Compounded Injection, 10 or 50 mg/mL, as follows (see *Pharmaceutical Compounding—Sterile Preparations* ⟨797⟩).

10-mg/mL Morphine Sulfate Compounded Injection

Morphine sulfate pentahydrate[a]	1 g
Sodium Chloride	760 mg
Sterile Water for Injection, a sufficient quantity to make	100 mL

[a] Morphine Sulfate, *USP*, is morphine sulfate pentahydrate; therefore no additional calculation is needed to account for the waters of hydration.

50-mg/mL Morphine Sulfate Compounded Injection

Morphine sulfate pentahydrate[a]	5 g
Sodium Chloride	450 mg
Sterile Water for Injection, a sufficient quantity to make	100 mL

[a] Morphine Sulfate, *USP*, is morphine sulfate pentahydrate; therefore no additional calculation is needed to account for the waters of hydration.

Dissolve the *Morphine sulfate pentahydrate* and *Sodium Chloride* in *Sterile Water for Injection* in a suitable calibrated container. Add sufficient *Sterile Water for Injection* to bring to final volume and mix well. Pass through a sterile filter of 0.22-µm pore size into sterile container(s).

ASSAY

• **Procedure**

Solution A: Dissolve 5.44 g of dibasic potassium phosphate in 800 mL of water and add 200 mL of methanol.

Mobile phase: See *Table 1*.

Table 1

Time (min)	Methanol (%)	Solution A (%)
0.0	0	100
3.0	0	100
8.0	45	55
13.0	45	55
13.1	0	100
20.0	0	100

Standard solution: 1 mg/mL of morphine sulfate pentahydrate prepared from USP Morphine Sulfate RS in water

Sample solution: Transfer 0.4 mL of the Injection into a 100-mL volumetric flask, and dilute with water to volume.

Chromatographic system

(See *Chromatography ⟨621⟩, System Suitability*.)

Mode: LC

Detector: UV 210 nm

Column: 4.6-mm × 15-cm; 5-µm packing L1

Flow rate: 1.0 mL/min

Injection volume: 15 µL

System suitability

Sample: *Standard solution*

[NOTE—The retention time for morphine sulfate is about 10.5 min.]

Suitability requirements

Tailing factor: NMT 2.0

Relative standard deviation: NMT 2.0% for replicate injections

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of morphine sulfate pentahydrate $[(C_{17}H_{19}NO_3)_2 \cdot H_2SO_4 \cdot 5H_2O]$ in the portion of Injection taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response from the *Sample solution*

r_S = peak response from the *Standard solution*

C_S = concentration of USP Morphine Sulfate RS in the *Standard solution* (mg/mL)

C_U = nominal concentration of morphine sulfate pentahydrate in the *Sample solution* (mg/mL)

Acceptance criteria: 90.0%–110.0%

SPECIFIC TESTS

- **pH ⟨791⟩:** 2.5–6.5
- **Sterility Tests ⟨71⟩, *Test for Sterility of the Product to Be Examined, Membrane Filtration*:** Meets the requirements
- **Bacterial Endotoxins Test ⟨85⟩:** It contains NMT 17.0 USP Endotoxin Units/mg of morphine sulfate. If labeled for intrathecal use, it contains NMT 14.29 USP Endotoxin Units/mg of morphine sulfate.
- **Particulate Matter in Injections ⟨788⟩:** It meets the requirements.

ADDITIONAL REQUIREMENTS

- **Packaging and Storage:** Package in sterile syringes for single-use in one patient only, protected from light. Store at controlled room temperature.

Change to read:

- **Beyond-Use Date:** ▲In the absence of performing and completing a sterility and endotoxin test, the storage conditions in *Pharmaceutical Compounding – Sterile Preparations ⟨797⟩, 14.3 Establishing a BUD for a CSP* apply.▲ (CN 1-Nov-2023) After successful completion of sterility and endotoxin testing, NMT 90 days after the date on which it was compounded when stored at controlled room temperature.
- **Labeling:** Label it to indicate that it is for use in a single patient only. Label it to indicate that it is preservative-free. Label it to state the *Beyond-Use Date*.
- **USP Reference Standards ⟨11⟩**
  USP Morphine Sulfate RS

Auxiliary Information - Please check for your question in the FAQs before contacting USP.

Topic/Question	Contact	Expert Committee
MORPHINE SULFATE COMPOUNDED INJECTION	Brian Serumaga Science Program Manager	CMP2020 Compounding 2020

Chromatographic Database Information: Chromatographic Database

Most Recently Appeared In:
Pharmacopeial Forum: Volume No. 45(2)

Current DocID: GUID-4FC1F38F-064C-4F73-8E5C-E02F805E7143_8_en-US
DOI: https://doi.org/10.31003/USPNF_M10968_08_01
DOI ref: o8sts